Oculis   Report issue

For profit Phase 2 Phase 3
Founded: Lausanne Switzerland (2017)
Status: No NME R&D (2017)

Organization Overview

First Clinical Trial
2017
NCT05343156
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Oculis

Active Ingredients

Drugs in Phase 3 Trials (1)

dexamethasone (7 trials)

Drugs in Phase 2 Trials (2)

cyclodextrin (1 trial)

licaminlimab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cataract (Phase 2)

Inflammation (Phase 2)

Keratitis (Phase 2)

Pain, Postoperative (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 3